JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3426
vTv Therapeutics
VTVT
$126M
| $1.26M | ﹤0.01% |
5,255
+3,187
| +154% | +$715K |
2017 Q3
1 quarter
|
|
3427
Vanguard S&P Mid-Cap 400 Growth ETF
IVOG
$1.6B
| $1.26M | ﹤0.01% |
18,958
-100,000
| -84% | -$6.54M |
2017 Q3
1 quarter
|
|
|
HALL
3428
DELISTED
Hallmark Financial Services, Inc.
HALL
| $1.26M | ﹤0.01% |
12,070
-192
| -2% | -$21.3K |
2013 Q2
18 quarters
|
|
3429
Mercantile Bank Corp
MBWM
$1.02B
| $1.26M | ﹤0.01% |
35,582
+3,657
| +11% | +$131K |
2016 Q2
6 quarters
|
|
|
NXGN
3430
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $1.26M | ﹤0.01% |
92,598
+54,723
| +144% | +$786K |
2016 Q4
4 quarters
|
|
|
QUOT
3431
DELISTED
Quotient Technology Inc
QUOT
| $1.26M | ﹤0.01% |
+107,025
| New | +$1.48M |
2017 Q4
0 quarters
|
|
|
CBD
3432
DELISTED
Companhia Brasileira de Distribuicao
CBD
| $1.26M | ﹤0.01% |
53,325
+51,525
| +2,863% | +$1.19M |
2017 Q2
2 quarters
|
|
3433
Oil States International
OIS
$494M
| $1.25M | ﹤0.01% |
44,069
-75,710
| -63% | -$1.84M |
2013 Q2
18 quarters
|
|
3434
Invesco S&P SmallCap 600 Revenue ETF
RWJ
$1.95B
| $1.24M | ﹤0.01% |
53,361
+11,583
| +28% | +$263K |
2015 Q2
10 quarters
|
|
3435
Foster
FSTR
$382M
| $1.24M | ﹤0.01% |
45,704
-10,259
| -18% | -$247K |
2016 Q2
6 quarters
|
|
|
DOC
3436
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $1.24M | ﹤0.01% |
69,007
+59,725
| +643% | +$1.07M |
2015 Q4
8 quarters
|
|
|
KA
3437
DELISTED
Kineta, Inc. Common Stock
KA
| $1.24M | ﹤0.01% |
1,519
-6,514
| -81% | -$2.5M |
2016 Q1
7 quarters
|
|
3438
PIMCO 1-5 Year US TIPS Index Exchange-Traded Fund
STPZ
$526M
| $1.24M | ﹤0.01% |
23,840
+2,043
| +9% | +$106K |
2015 Q3
9 quarters
|
|
3439
iShares US Broker-Dealers & Securities Exchanges ETF
IAI
$1.32B
| $1.24M | ﹤0.01% |
+19,714
| New | +$1.18M |
2017 Q4
0 quarters
|
|
3440
Braskem
BAK
$618M
| $1.24M | ﹤0.01% |
47,052
-116,304
| -71% | -$3.32M |
2015 Q3
9 quarters
|
|
3441
CALL
Editas Medicine
EDIT
$387M
| $1.23M | ﹤0.01% |
+40,000
| New | +$1.01M |
2017 Q4
0 quarters
|
|
|
3442
PUT
Editas Medicine
EDIT
$387M
| $1.23M | ﹤0.01% |
+40,000
| New | +$1.01M |
2017 Q4
0 quarters
|
|
|
BKI
3443
DELISTED
Black Knight, Inc. Common Stock
BKI
| $1.23M | ﹤0.01% |
27,815
+27,651
| +16,860% | +$1.25M |
2015 Q4
8 quarters
|
|
|
TGB
3444
Trekor Metals
TGB
$3.04B
| $1.22M | ﹤0.01% |
524,834
+379,537
| +261% | +$822K |
2017 Q1
3 quarters
|
|
|
SRC.PRA
3445
CALL
DELISTED
Spirit Realty Capital, Inc. 6.000 Percent Series A Cumulative Redeemable Preferred Stock
SRC.PRA
| $1.22M | ﹤0.01% |
+142,100
| New | +$3.49M |
2017 Q4
0 quarters
|
|
3446
CALL
Sprouts Farmers Market
SFM
$6.01B
| $1.22M | ﹤0.01% |
50,000
-205,500
| -80% | -$4.36M |
2017 Q3
1 quarter
|
|
3447
Armstrong World Industries
AWI
$6.88B
| $1.22M | ﹤0.01% |
20,086
+19,574
| +3,823% | +$1.08M |
2015 Q1
11 quarters
|
|
3448
Hawkins
HWKN
$2.66B
| $1.22M | ﹤0.01% |
69,174
-6,354
| -8% | -$122K |
2016 Q2
6 quarters
|
|
|
OCLR
3449
CALL
DELISTED
Oclaro Inc.
OCLR
| $1.21M | ﹤0.01% |
180,000
| – | – |
2016 Q4
4 quarters
|
|
|
OCLR
3450
PUT
DELISTED
Oclaro Inc.
OCLR
| $1.21M | ﹤0.01% |
180,000
-50,000
| -22% | -$369K |
2016 Q4
4 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.